149 related articles for article (PubMed ID: 37838554)
1. Re: Roberto Contieri, Patrick J. Hensley, Wei Shen Tan, et al. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy. Eur Urol Oncol. 2023;6:590-596.
Montorsi F; Rosiello G; Gandaglia G
Eur Urol Oncol; 2024 Apr; 7(2):300. PubMed ID: 37838554
[No Abstract] [Full Text] [Related]
2. Reply to Francesco Montorsi, Giuseppe Rosiello, and Giorgio Gandaglia's Letter to the Editor re: Roberto Contieri, Patrick J. Hensley, Wei Shen Tan, et al. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy. Eur Urol Oncol. 2023;6:590-596.
Contieri R; Hensley PJ; Kamat AM
Eur Urol Oncol; 2024 Apr; 7(2):301. PubMed ID: 37806840
[No Abstract] [Full Text] [Related]
3. Re: Wei Shen Tan, Ian M. McElree, Facundo Davaro, et al. Sequential Intravesical Gemcitabine and Docetaxel Is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. 2023;6:531-534.
Sung WW
Eur Urol Oncol; 2024 Feb; 7(1):163. PubMed ID: 37679244
[No Abstract] [Full Text] [Related]
4. Re: Wei Shen Tan, Aaron Prendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003.
Sahoo S; Pandey A; Mandal S; Kumar Das M; Nayak P
Eur Urol; 2023 Feb; 83(2):e47. PubMed ID: 36404203
[No Abstract] [Full Text] [Related]
5. Re: Wei Shen Tan, Aaron Prendergast, Charlotte Ackermann, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003.
Campodonico F; Mattioli F; Introini C
Eur Urol; 2023 Feb; 83(2):e56-e57. PubMed ID: 36372625
[No Abstract] [Full Text] [Related]
6. Reply to Fabio Campodonico, Francesca Mattioli, and Carlo Introini's Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003.
Tan WS; Kelly JD;
Eur Urol; 2023 Jan; 83(1):e29-e30. PubMed ID: 36272948
[No Abstract] [Full Text] [Related]
7. Re: Pawel Rajwa, Daniele Robesti, Michael Chaloupka, et al. Outcomes of Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer on Prostate-specific Membrane Antigen Positron Emission Tomography: Results of a Multicenter European Study. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.09.006.
Onal C; Elmali A; Cem Guler O
Eur Urol Oncol; 2024 Jun; 7(3):644-645. PubMed ID: 38365504
[No Abstract] [Full Text] [Related]
8. Re: Francesco Soria, Matteo Rosazza, Simone Livoti, et al. Repeat Transurethral Resection (TUR) + Bacillus Calmette-Guérin (BCG) Versus Upfront Induction BCG After TUR in High-risk Non-muscle-invasive Bladder Cancer: Feasibility Phase of a Randomized Controlled Study. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.10.019.
Montorsi F; Moschini M; Salonia A; Gandaglia G; Briganti A
Eur Urol Focus; 2024 Jan; ():. PubMed ID: 38272719
[No Abstract] [Full Text] [Related]
9. Reply to Suman Sahoo, Abhishek Pandy, Swarnendu Mandal, Manoj Kumar Das, and Prasant Nayak's Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003.
Tan WS; Mustard C; Kelly JD;
Eur Urol; 2023 Feb; 83(2):e48-e49. PubMed ID: 36456403
[No Abstract] [Full Text] [Related]
10. Re: Kristian D. Stensland, Harras Zaid, Mark Broadwin, et al. Comparative Effectiveness of Treatment Strategies for Squamous Cell Carcinoma of the Bladder. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2018.11.003.
Moschini M; Zamboni S; Mattei A
Eur Urol Oncol; 2019 Mar; 2(2):230. PubMed ID: 31017104
[No Abstract] [Full Text] [Related]
11. Reply to Marc A. Furrer and Patrick Y. Wuethrich's and Francesco Montorsi, Marco Moschini, Giorgio Gandaglia, and Alberto Briganti's Letters to the Editor re: Jakob Klemm, Michael Rink, Markus Von Deimling, et al. Time-to-complication Patterns After Radical Cystectomy: A Secondary Analysis of a 30-day Morbidity Assessment Using the European Association of Urology Quality Criteria for Standardized Reporting. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.06.005.
Klemm J; Koelker M; Shariat SF; Fisch M; Vetterlein MW
Eur Urol Focus; 2023 Oct; ():. PubMed ID: 37806850
[No Abstract] [Full Text] [Related]
12. Re: David D'Andrea, Francesco Soria, Rodolfo Hurle, et al. En Bloc Versus Conventional Resection of Primary Bladder Tumor (eBLOC): A Prospective, Multicenter, Open-label, Phase 3 Randomized Controlled Trial. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.07.010.
Lombardo R; Riolo S; De Nunzio C
Eur Urol Oncol; 2023 Oct; ():. PubMed ID: 37872030
[No Abstract] [Full Text] [Related]
13. Re: David D'Andrea, Francesco Soria, Rodolfo Hurle, et al. En Bloc Versus Conventional Resection of Primary Bladder Tumor (eBLOC): A Prospective, Multicenter, Open-label, Phase 3 Randomized Controlled Trial. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.07.010.
Montorsi F; Rosiello G; Gandaglia G; Salonia A; Briganti A
Eur Urol Oncol; 2024 Jun; 7(3):636. PubMed ID: 37951819
[No Abstract] [Full Text] [Related]
14. Reply to Marco Moschini, Francesco Montorsi, Andrea Salonia, Giorgio Gandaglia and Alberto Briganti's Letter to the Editor Re: Francesco Soria, Matteo Rosazza, Simone Livoti, et al. Repeat Transurethral Resection (TUR) + Bacillus Calmette-Guérin (BCG) Versus Upfront Induction BCG After TUR in High-risk Non-muscle-invasive Bladder Cancer: Feasibility Phase of a Randomized Controlled Study. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.10.019.
Soria F; Gontero P
Eur Urol Focus; 2024 Jan; ():. PubMed ID: 38278711
[No Abstract] [Full Text] [Related]
15. Re: Gopal Sharma, Milap Shah, Puneet Ahluwalia, et al. Off-clamp Versus On-clamp Robot-assisted Partial Nephrectomy: A Propensity-matched Analysis. Eur Urol Oncol. 2023;6:525-530.
Bertolo R; Bove P; Antonelli A;
Eur Urol Oncol; 2024 Apr; 7(2):309-310. PubMed ID: 37661461
[No Abstract] [Full Text] [Related]
16. Re: Ost P, Siva S, Brabrand S, et al. PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.09.007.
Montorsi F; Gandaglia G; Barletta F; Briganti A
Eur Urol Oncol; 2024 Feb; ():. PubMed ID: 38418265
[No Abstract] [Full Text] [Related]
17. Re: E. Jason Abel, Viraj A. Master, Philippe E. Spiess, et al. The Selection for Cytoreductive Nephrectomy (SCREEN) Score: Improving Surgical Risk Stratification by Integrating Common Radiographic Features. Eur Urol Oncol. 2023;6:266-274.
Roussel E; Bertolo R; Ciccarese C; Marandino L; Marchioni M; Campi R; Albersen M;
Eur Urol Oncol; 2024 Apr; 7(2):304-305. PubMed ID: 37981494
[No Abstract] [Full Text] [Related]
18. Re: Jakob Klemm, Michael Rink, Markus von Deimling, et al. Time-to-complication Patterns After Radical Cystectomy: A Secondary Analysis of a 30-day Morbidity Assessment Using the European Association of Urology Quality Criteria for Standardized Reporting. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.06.005.
Furrer MA; Wuethrich PY
Eur Urol Focus; 2023 Oct; ():. PubMed ID: 37806852
[No Abstract] [Full Text] [Related]
19. Re: Jakob Klemm, Michael Rink, Markus von Deimling, et al. Time-to-complication Patterns After Radical Cystectomy: A Secondary Analysis of a 30-day Morbidity Assessment Using the European Association of Urology Quality Criteria for Standardized Reporting. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.06.005.
Montorsi F; Moschini M; Gandaglia G; Briganti A
Eur Urol Focus; 2023 Sep; ():. PubMed ID: 37748951
[No Abstract] [Full Text] [Related]
20. Reply to Riccardo Lombardo, Sara Riolo, and Cosimo De Nunzio's Letter to the Editor re: David D'Andrea, Francesco Soria, Rodolfo Hurle, et al. En Bloc Versus Conventional Resection of Primary Bladder Tumor (eBLOC): A Prospective, Multicenter, Open-label, Phase 3 Randomized Controlled Trial. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.07.010.
D'Andrea D; Soria F; Hurle R; Enikeev D; Kotov S; Régnier S; Xylinas E; Lusuardi L; Heidenreich A; Cai C; Frego N; Taraktin M; Ryabov M; Gontero P; Compérat E; Shariat SF;
Eur Urol Oncol; 2023 Oct; ():. PubMed ID: 37865570
[No Abstract] [Full Text] [Related]
[Next] [New Search]
